Comparison of highly pure rAAV9 vector stocks produced in suspension by PEI transfection or HSV infection reveals striking quantitative and qualitative differences
Open Access
- 25 December 2021
- journal article
- research article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 24, 154-170
Abstract
No abstract availableKeywords
Funding Information
- University of Florida
This publication has 43 references indexed in Scilit:
- Properties of the Adeno-Associated Virus Assembly-Activating ProteinJournal of Virology, 2012
- Reproducible High Yields of Recombinant Adeno-Associated Virus Produced Using Invertebrate Cells in 0.02- to 200-Liter CulturesHuman Gene Therapy, 2011
- Phase 2 Clinical Trial of a Recombinant Adeno-Associated Viral Vector Expressing α 1 -Antitrypsin: Interim ResultsHuman Gene Therapy, 2011
- Good Manufacturing Practice Production of Self-Complementary Serotype 8 Adeno-Associated Viral Vector for a Hemophilia B Clinical TrialHuman Gene Therapy, 2011
- Preclinical Evaluation of a Recombinant Adeno-Associated Virus Vector Expressing Human Alpha-1 Antitrypsin Made Using a Recombinant Herpes Simplex Virus Production MethodHuman Gene Therapy, 2010
- Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at ScaleHuman Gene Therapy, 2010
- Large-Scale Adeno-Associated Viral Vector Production Using a Herpesvirus-Based System Enables Manufacturing for Clinical StudiesHuman Gene Therapy, 2009
- Gene Therapy Using Adeno-Associated Virus VectorsClinical Microbiology Reviews, 2008
- High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cellsBiotechnology Letters, 2007
- Scalable production of adeno‐associated virus type 2 vectors via suspension transfectionBiotechnology and Bioengineering, 2006